SCORAD Index (SCORing Atopic Dermatitis)
SCORing Atopic Dermatitis · Also known as: SCORAD Index
The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
SCORAD is indicated in specialist dermatology settings (secondary and tertiary care) for patients with moderate-to-severe atopic dermatitis. It is essential in clinical trials and for baseline/longitudinal monitoring of systemic therapy. It requires clinician training and is less practical in primary care due to time and expertise demands. SCORAD is preferred over simple extent-only measures because it captures both objective disease burden and subjective impact.
Strengths & limitations
- Validated globally with strong inter-rater and test-retest reliability.
- Combines objective clinical assessment with patient-reported outcomes (pruritus and sleep disruption).
- Sensitive to change over time; responsive to topical and systemic treatments.
- Recommended as a primary endpoint in international clinical trials by regulatory agencies.
- Captures the full spectrum of disease severity from mild to severe.
- Requires trained clinician administration; not suitable for patient self-assessment or remote monitoring.
- Time-consuming (10–15 minutes); impractical for high-volume primary care clinics.
- Subjective extent estimation (percentage body surface area) introduces variability; inter-rater agreement for extent is moderate.
- VAS components (pruritus, sleep loss) can fluctuate daily, potentially causing score instability.
- Ceiling effects may limit ability to detect changes in very mild disease.
Frequently asked
What is the difference between SCORAD and EASI?
SCORAD includes pruritus and sleep loss as subjective components, whereas EASI does not. EASI uses a four-region body division and adds a frequency modifier, making it more structured. Both are valid, but SCORAD is preferred when patient symptom burden is central to the clinical question. EASI is often used in trials focused on objective clinical improvement.
Can patients self-administer SCORAD?
No. SCORAD requires trained clinician assessment of six skin signs and clinical judgment about extent. Patient self-assessment is unreliable and invalidates the score. The subjective components (pruritus VAS, sleep loss VAS) are patient-reported, but the examination portion must be clinician-led.
What is the minimal clinically important difference (MCID) for SCORAD?
A reduction of ≥8.7 SCORAD points is considered clinically significant improvement. However, in pediatric populations and very severe disease, interpretations may vary by context. Always report absolute change and percentage change from baseline.
How often should SCORAD be repeated?
In clinical practice, SCORAD is typically reassessed every 4–12 weeks during active treatment escalation, and every 3–6 months during maintenance. In clinical trials, assessment intervals are protocol-specific but commonly occur at baseline, Week 4, Week 12, and final visit. Frequent assessment (weekly) is not recommended due to daily symptom fluctuation.
Is SCORAD suitable for telemedicine or remote assessment?
The objective examination component (clinical signs, extent) cannot be reliably assessed remotely. Some centers have piloted photographic assessment or video examination, but these have not been formally validated and carry significant inter-rater variability risk. Remote SCORAD is not recommended as a replacement for in-person assessment in clinical care or trials.
Sources
- Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19. DOI: 10.1159/000245677 ↗
- Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44-47. link ↗
How to cite this page
ScholarGate. (2026, June 3). SCORing Atopic Dermatitis. ScholarGate. https://scholargate.app/en/dermatology/scorad
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →